TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07775287: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-

Sponsor: Genmab · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07775287 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07775287 Rescue Dossier →